Abstract
Chronic urticaria, defined as having urticaria for over 6 weeks, is
divided into two categories; namely, inducible urticaria and chronic
spontaneous urticaria (CSU). Inducible urticarias have an initiating
stimulus, often “physical”, and actually occur intermittently, but the
total duration of symptoms can encompass many years. CSU is more
typically chronic, has urticarial lesions most days of the week, has no
exogenous cause, and from the patient’s point of view, does seem
spontaneous. An algorithm for the diagnosis of CSU is shown in Fig. 1.
Angioedema can accompany many inducible urticarias, but is more
typically associated with CSU affecting face, extremities, genitalia,
lips, tongue, and rarely pharynx, but not the larynx. Thus risk of
asphyxiation is nil. The disorder is strongly associated with
autoimmunity. The best studied (often referred to as type IIb
autoimmunity) involves IgG antibody to the IgE
receptor[1](#ref-0001) which cross-links unoccupied IgE receptors
of mast cells and activates the cells to cause secretion of histamine,
leucotrienes, cytokines, and chemokines. Complement is activated and
release of C5a augments the mast cell secretion[2](#ref-0002).
There is a second scenario in which patients have IgE antibody to a
large variety of autoantigens[3](#ref-0003) including
thyroperoxidase and interleukin 24, although which are pathogenic is not
yet clear. This is often designated as type I autoimmunity or
autoallergy. Clinically, other autoimmune disorders may be present. The
most prominent is Hashimoto’s thyroiditis, but also type I diabetes and
vitiligo. Antithyroid antibodies (i.e. IgG anti microsomal antigen and
IgG antithyroglobulin) are seen in 25% of patients regardless of
thyroid status. Total IgE is elevated within this population although
much less so than in asthma or atopic dermatitis. Low or very low IgE
levels may be seen and such patients are less responsive to
omalizumab[4](#ref-0004).